OREGON CLINICAL & TRANSLATIONAL RESEARCH INSTITUTE

Biomedical Innovation Program (BIP) Device, Diagnostic & Software

REQUEST FOR APPLICATIONS

The Oregon Clinical & Translational Research Institute (OCTRI) in partnership with OHSU Technology Transfer and OHSU Collaborations and Entrepreneurship, is accepting letters of intent for the Biomedical Innovation Program (BIP) Device, Diagnostic, and Software track.

PROGRAM OVERVIEW

BIP Device, Diagnostic, and Software supports the development and commercialization of novel and innovative technologies which aim to improve healthcare delivery. Proposed medical device and diagnostic technologies should address a significant clinical problem, achieve cost savings, improve research efficiency, or improve quality of patient care.

Grants will be awarded on a competitive basis, with budgets not to exceed $40,000. Additionally, each awardee will be assigned a project manager and a mentor to advise and help accelerate their project towards commercialization. Projects will typically be supported for a 12-month period; predetermined milestones and quantitative metrics of success will be evaluated on a regular basis.

APPLICATION PROCESS OVERVIEW

1. Submit a ***Technology Disclosure Form*** to OHSU Technology Transfer.

2. Review the application resources on the BIP webpage and contact Jonathan Jubera jubera@ohsu.edu with questions about the program and/or application process.

4. Submit a letter of intent (LOI) that is no more than ***2 pages*** long. Please use the ***template*** provided in page 3. Letters of support are encouraged (up to 2) and do not count toward the page limit. Submit your LOI via REDCap by clicking ***here***.

5. Projects selected to advance will be asked to submit a 5-page, full application and be invited to participate in a Q&A with review committee members.

6. Finalists will be invited to present to the review committee, after which, final funding decisions will be made.

All letters of intent and full applications are treated as confidential documents. Confidentiality agreements are in place with all members of the review committee.

KEY DATES

Letter of Intent (LOI) due: ***9/15/26***

Full application due: ***10/26/26***

Q&A with reviewers: ***11/12/26***

Final presentation: ***12/10/26***

NEED ASSISTANCE WITH YOUR APPLICATION?

To learn more about the BIP or to schedule a consult, please contact:

Jonathan Jubera, M.B.A.
Senior Project Manager
jubera@ohsu.edu

APPLICATION RESOURCES ARE AVAILABLE AT:

https://www.ohsu.edu/octri/biomedical-innovation-program-academia-marketplace

LEARN HOW TO VALIDATE YOUR IDEA

BIP CORP

REVIEW CRITERIA

- ***Leverage pilot funding:*** Will the stated milestones position the technology for follow-on funding and are they aligned with a path to commercialization?
- ***Impact to human health:*** Does the proposed work aim to solve an important problem or remove a critical barrier to progress in the field? Is the unmet medical need for the technology appropriately described?
- ***Market need addressed:*** Is the market need articulated and supported with data such as number of patients likely affected, expected savings in health care/societal expenditures, etc.?
- ***Project design and feasibility:*** Is the proposed work feasible? What types of expertise will be leveraged to move the technology forward? What are the potential barriers, and what is the plan to overcome them?
- ***Innovation and novelty:*** How strong is the potential for the proposed technology to be novel, useful, non-obvious, and enabled? What niche does it fill?
- ***Commercialization potential:*** Are the next steps towards commercialization well described and potential funding sources identified to carry them out? Are there target entities identified as potential partners or licensees? Is there interest or potential for creating a start-up?
- ***Strength of team:*** Do the investigators have the requisite skills, experience, and capacity to carry out the project successfully?

ELIGIBILITY

BIP Device, Diagnostic, and Software is open to all employees and students of OHSU, with these important caveats:

- If either human subjects or animals are included in the project scope of work, the applicant MUST meet ***OHSU Principal Investigator*** requirements.
- Non-faculty applicants must submit written approval from their supervisor or department head authorizing "effort" on the grant – including the specific amount.

PROJECTS INVOLVING HUMAN SUBJECTS RESEARCH AND/OR LIVE VERTEBRATE ANIMAL STUDIES

In addition to IRB/IACUC approval, the National Center for Advancing Translational Science (NCATS) must approve human subjects research and/or live vertebrate animal projects before any funding can be released. Applicants are strongly urged to complete the required components of the NCATS submission(s) during the application phase to reduce the time to funding. Please contact Bridget Adams, OCTRI Regulatory Knowledge and Support Manager, for a list of the required elements and assistance: adamsb@ohsu.edu.

POST-AWARD PROCESSES

During the project period predetermined milestones and quantitative metrics of success will be evaluated on a regular basis. All award recipients will be required to submit a final report that summarizes the work completed, barriers or challenges that hindered completion of milestones and next steps for moving the technology forward toward commercialization. More information about awardee responsibilities is included in the REDCap submission form.

QUESTIONS?

Please direct all questions Jonathan Jubera (jubera@ohsu.edu, 503-805-8179).

BIOMEDICAL INNOVATION PROGRAM (BIP) DEVICE, DIAGNOSTIC, & SOFTWARE – LETTER OF INTENT TEMPLATE

Please use the headings below to complete your LOI before uploading via REDCap. ***LOI should not exceed 2 pages****. References and letters of support (maximum of 2) do not count toward the two-page limit and should be uploaded with the LOI.*

PRINCIPAL INVESTIGATOR (NAME AND TITLE):

PROJECT TITLE:

BACKGROUND/UNMET NEED: *Describe the unmet or poorly met clinical need or disease, including the current approaches for assessment or treatment of your chosen clinical problem and the known shortcomings of those approaches. Make it clear what the problem is that you are trying to solve or make better.*

PROPOSED TECHNOLOGY AND SOLUTION: *Describe your solution and the advantages it would have compared to current approaches. Include preliminary data. Explain how your technology addresses the problem you are trying to solve.*

MARKET OPPORTUNITY: *Explain what is clinically significant about your proposed device, diagnostic, or software technology. Please outline the market need including metrics such as the number of patients likely affected, expected savings in health care/societal expenditures, etc. Research and estimate the total addressable market (TAM), what portion of it can you obtain and how? Look at the market for existing/competing products now and forecast what it might be at the end of the development process.*

COMPETITION: *Identify current competitors and explain why your solution be used instead.*

INTELLECTUAL PROPERTY: *State the intellectual property status, strategy, and future plans. Include invention disclosures, filed patent applications, IP ownership shared with others, patents awarded and/or technologies licensed, and third- party existing IP related to your proposed technology. IP is considered critical for future financing.*

R&D TIMELINE AND BUDGET: *Outline 12-month project timeline and milestones. Include a gross estimate of the direct R&D costs for study personnel, minor equipment, and supplies (do not add in the university overhead) for the award period. Please include commercial planning activities in this section and identify substantial post-BIP milestones. Consider using a visual aid to show time to milestones and projected costs. Describe any significant risks you perceive with the proposed work and getting to the next substantial milestone. If there is an opportunity to de-risk later development with the BIP funding, please explain.*

COMMERCIALIZATION POTENTIAL: *Describe a strategy for pursuing additional funding (e.g., sponsored research agreements, industry partners, or additional grants to further commercial development after BIP funding ends). What is the planned or desired commercialization path: licensing the technology to an existing company or forming a startup company? Make sure to explain why your solution will be adopted.*

TEAM MEMBERS: *List team members, their expertise, and project role. Make clear why the team can and will make this project a success.*